Capability
Post-launch execution
Approval opens a new evidence problem set: how the product performs in heterogeneous populations, how payers interpret utilization, and how medical affairs can speak credibly as competitors and guidelines evolve. We build the post-launch engine—studies, analytics, and narratives—that keeps the constellation current.
Launch is rarely the end of the evidence journey; it is the handoff from controlled trials to practice reality. Payers, guidelines committees, and competitors move quickly. We help you prioritize ISS, registries, and real-world analytics so each investment reinforces the label, supports access, and avoids contradictions that erode trust with regulators or the public.
The post-approval challenge
After approval, medical affairs, market access, and HEOR teams inherit a label and a set of trial narratives that may not fully answer questions from payers, specialty societies, or community prescribers. Real-world data promise speed, but poor study design, biased cohorts, or over-interpreted analyses can damage credibility with the same stakeholders you need for sustainable utilization. Meanwhile, competitors launch, treatment pathways shift, and internal pressure mounts to “prove” value with whatever data are cheapest to access.
The organizations that perform best treat post-launch evidence as a portfolio: a sequenced mix of ISS, pragmatic studies, registries, and secondary data analyses—each tied to explicit claims, access defenses, or medical education needs. We help you build that portfolio with the same discipline applied to registrational development, adapted to the faster cycle times and messier data of the real world.
Where we focus
RWE and evidence-generation strategy
We draft study concepts, target populations, and endpoint sets that align with label boundaries and access arguments. That includes feasibility assessment for chart review versus prospective registries, hybrid designs, and patient-reported add-ons where trial PROs were thin. We emphasize transparency in limitations and pre-specification where possible, so outputs withstand scrutiny from methodologists and payer reviewers.
Secondary data and analytics
Claims, EMR, and specialty pharmacy datasets each have blind spots. We help teams choose data sources and analytic approaches that match the question—switching and sequencing, adherence, safety signals in broader populations, or comparative utilization—without implying causal inference the design cannot support. Where advanced methods add value, we pair them with plain-language summaries field and access teams can use.
Medical affairs and field enablement
MSLs and medical directors need narratives grounded in evidence hierarchies: what is registrational, what is supportive, and what is exploratory. We build slide logic, objection handlers, and publication roadmaps that keep the scientific story consistent across geographies and channels, including digital and congress formats.
Lifecycle roadmaps and governance
We maintain rolling evidence calendars that connect ISS, RWE, health economics updates, and potential label changes—so leadership sees trade-offs between spend, risk, and competitive timing. Governance includes review of claims language, coordination with pharmacovigilance, and escalation paths when emerging data conflict with prior positions.
What we deliver
- RWE protocol outlines, SAP concepts, and publication plans aligned to MA and access priorities.
- Data-source assessments and analytic plans for claims, EMR, and specialty channels.
- Competitive intelligence syntheses tying trial, RWE, and pricing narratives to your differentiation story.
- Payer-facing summaries of real-world analyses with explicit limitations and “do not say” guardrails.
- Cross-functional launch and post-launch workshops—medical, HEOR, access, stats—with decision logs.
- Integration points with economic models when RWE outputs feed budget-impact or cost-effectiveness updates.
Outcomes you can expect
- A prioritized post-launch evidence agenda instead of a backlog of unfunded study ideas.
- Fewer fire drills when payers or competitors challenge your evidence base.
- Clearer boundaries on what medical and commercial teams can claim by channel and audience.
- Better use of analytics budgets—fewer redundant studies, more compounding evidence over time.
How we work
We trace every major post-launch evidence initiative back to the label, the access strategy, and the competitive landscape. lotor lab does not treat RWE as a parallel track to clinical development; we treat it as the continuation of the same constellation of evidence, with different methods and tolerances for bias.
Where machine learning or high-dimensional data add insight—heterogeneity of treatment effect, site variation, early safety signals—we insist on interpretability for medical and legal reviewers. We collaborate with your internal epidemiologists, data science teams, and vendors; our role is to keep questions, methods, and messaging aligned with enterprise risk tolerance.
When teams bring us in
- Launch readiness, when MA, HEOR, and access must agree on a 12–36 month evidence calendar.
- Access negotiations or formulary decisions requiring rapid, defensible characterization of use and outcomes.
- Competitive or guideline shifts that obsolete prior medical narratives.
- Post-marketing commitments, label expansions, or safety updates that require new studies or analyses.